Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.91 |
| ▸ | FAAH | O00519 | 1/20 | 0.91 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.91 |
| ▸ | CNR2 | P34972 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linoleoylethanolamide SCHEMBL653623 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| SCHEMBL30306296 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| SCHEMBL14106445 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| SCHEMBL14864036 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| Linoleoylethanolamide SCHEMBL5145794 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| SCHEMBL5412597 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| SCHEMBL14106447 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| SCHEMBL17097089 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| Linoleoylethanolamide SCHEMBL13110450 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| SCHEMBL1334847 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022217147-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | ROSENFELD MARK J (US) | 2022-10-13 | — | — | WO | claimed |
| EP-2704793-B1 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV RAMOT (IL) | 2019-07-17 | — | — | EP | claimed |
| US-9192670-B2 | Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-11-24 | — | — | US | claimed |
| EP-2704793-A1 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Ramot at Tel Aviv University, Ltd. (IL) | 2014-03-12 | — | — | EP | claimed |
| WO-2012150600-A2 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-11-08 | — | — | WO | claimed |
| EP-4694699-A2 | COMPOSITIONS AND METHODS OF CONTROLLING MAMMALIAN SATIETY | VitaKey Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025038374-A1 | METHODS OF IMPROVING MICROVASCULAR HEALTH | MARS, INCORPORATED (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2024216228-A2 | COMPOSITIONS AND METHODS OF CONTROLLING MAMMALIAN SATIETY | VITAKEY INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2023209548-A1 | LEONOTIS LEONURUS EXTRACTS AS A CHEMOPROTECTANT AND POST-CHEMOTHERAPEUTIC AGENT | STELLENBOSCH UNIVERSITY (ZA) | 2023-11-02 | — | — | WO | disclosed |
| WO-2022217147-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | ROSENFELD MARK J (US) | 2022-10-13 | — | — | WO | disclosed |
| EP-2704793-B1 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV RAMOT (IL) | 2019-07-17 | — | — | EP | disclosed |
| US-9326927-B2 | Use of cannabinoid compounds for stimulating melanogenesis | L'OREAL (FR) | 2016-05-03 | — | — | US | disclosed |
| US-20140074181-A1 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Ramot at Tel-Aviv Univerity Ltd. (IL) | 2014-03-13 | — | — | US | disclosed |
| EP-2704793-A1 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Ramot at Tel Aviv University, Ltd. (IL) | 2014-03-12 | — | — | EP | disclosed |
| US-8420602-B2 | May be coupled with endorphin, enkephalin, dynorphin or endomorphin; for traversing blood brain barrier | MILLER LANDON C G (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420602-B2 | May be coupled with endorphin, enkephalin, dynorphin or endomorphin; for traversing blood brain barrier | MILLER LANDON C G (US) | 2013-04-16 | — | — | US | disclosed |
| WO-2013021128-A2 | USE OF CANNABINOID COMPOUNDS FOR STIMULATING MELANOGENESIS | L'OREAL (FR) | 2013-02-14 | — | — | WO | disclosed |
| WO-2012150600-A2 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-11-08 | — | — | WO | disclosed |
| WO-2005023232-A2 | THERAPEUTIC, SCREENING AND DIAGNOSTIC METHODS BASED ON THE EFFECT OF CB1 RECEPTOR MODULATION ON LYMPHOPROLIFERATIVE DISORDERS. | AFFIBODY AB (SE) | 2005-03-17 | — | — | WO | disclosed |
| WO-2004078261-A1 | CANNABINOID RECEPTOR INVERSE AGONISTS AND NEUTRAL ANTAGONISTS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE DISORDERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2004-09-16 | — | — | WO | disclosed |